Navigation Links
Arecor Appoints Dr. Sarah Howell as Chief Operating Officer
Date:11/10/2011

CAMBRIDGE, England, November 10, 2011 /PRNewswire/ --

Arecor, the leading company in advancing aqueous formulation solutions for proteins, peptides and vaccines, is pleased to announce the appointment of Dr Sarah Howell as Chief Operating Officer.  Dr Howell will be responsible for the operations of Arecor, with a focus on developing and maintaining Arecor's upward growth curve ensuring the company continues to deliver exceptional formulation solutions and performance to the highest standards across the industry.

Dr Howell has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of products and therapeutic areas having worked in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had responsibility for CMC development and supply across BTG's diverse portfolio of products.  Previously she held senior roles in product development and manufacturing for UCB-Celltech and GlaxoSmithKline.  She is also an active member of the BioIndustry Association (BIA) Manufacturing Advisory Committee.  Dr Howell has an honours degree in Chemistry from the University of Birmingham and a PhD in Physical Organic Chemistry from the University of St Andrews.

Tom Saylor, CEO of Arecor stated "Sarah's considerable technical and leadership experience in the management of development programmes for biologic drugs, and her capabilities in building partnerships with major pharmaceutical companies will be a tremendous asset to Arecor as it expands its business in an industry looking to formulation as an enabling technology for the new generation of biologic drugs."

Arecor was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into stabilization of biologics.  Proteins and vaccines are often fragile entities, and stability can represent significant constraints in the development of new products and extending the use of existing products.  Arecor has developed Arestat™, a patented set of tools for stabilization which address the main pathways of degradation.  As a simple reformulation, Arestat™ can be readily incorporated into standard manufacturing practice, without covalent modification of the biologic and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines.

Contact:

Tom Saylor, CEO tsaylor@arecor.com
Arecor Ltd
2 Cambridge Science Park
Cambridge, UK
http://www.arecor.com
+44(0)1223-426060



'/>"/>
SOURCE Arecor
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Saladax Biomedical, Inc. Appoints Li Zhang, M.D., to Scientific Advisory Board
2. NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer
3. Virobay Appoints David B. Karpf, M.D. as Chief Medicial Officer
4. Axia Value Chain Appoints John Christina Managing Director of Life Sciences Practice
5. Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors
6. Metabolex Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer
7. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
8. Kessler Foundation Appoints New Director of Human Performance and Engineering Laboratory
9. China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee
10. Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer
11. Amgen Appoints Robert A. Bradway to the Companys Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... 2017 , ... At its national board meeting in North Carolina, ARCS® ... Departments of Physics and Astronomy, has been selected for membership in ARCS Alumni ... the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which ... video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). ...
(Date:10/7/2017)... Seattle, WA (PRWEB) , ... ... ... the industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome ... the ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C ...
Breaking Biology Technology:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
Breaking Biology News(10 mins):